Nephrology

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.

Results suggest the potential utility of several nutritional indexes for reflecting IgAN severity and predicting end-stage renal disease risk.

Findings link greater thiazide doses to increased reductions in urine calcium and fewer subsequent symptomatic kidney stone events.

A new study reveals dialysis increases life expectancy but reduces time at home for older adults below the eGFR threshold of 12 mL/min/1.73 m².

Care for dialysis patients often focuses on kidney health, but experts and a patient stress the need for interdisciplinary care that also addresses sleep health.

Findings from the bidirectional 2-sample Mendelian randomization study suggest a strong positive causal association between atopic dermatitis and IgAN.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.

Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.

Study findings suggest the need for individualized management of patients with IgAN following COVID-19 infection based on baseline renal function status.

Findings support the use of mineralocorticoid receptor antagonists for the short-term reduction of proteinuria in patients with IgAN.

This July 2024 month in review highlights renal pipeline updates, new patient-focused CKD guidelines, and other top nephrology news and research.

The acellular tissue engineered vessel met co-primary endpoints for function and patency at 6 and 12 months compared to autogenous fistula in patients on hemodialysis.

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.

The high diagnostic and prognostic application values of newer IgAN machine learning models suggest their eventual utility in clinical practice.

The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.

Findings suggest greater CTSS levels are associated with an elevated risk of IgAN and highlight the enzyme’s potential as a diagnostic biomarker.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.

Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.